Voya Investment Management LLC Reduces Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Voya Investment Management LLC trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 20.3% in the third quarter, Holdings Channel reports. The institutional investor owned 47,613 shares of the specialty pharmaceutical company’s stock after selling 12,101 shares during the quarter. Voya Investment Management LLC’s holdings in Supernus Pharmaceuticals were worth $2,275,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the stock. Contravisory Investment Management Inc. purchased a new position in Supernus Pharmaceuticals during the 3rd quarter valued at about $296,000. GAMMA Investing LLC boosted its position in shares of Supernus Pharmaceuticals by 107.3% in the third quarter. GAMMA Investing LLC now owns 5,932 shares of the specialty pharmaceutical company’s stock valued at $283,000 after acquiring an additional 3,071 shares during the period. Praxis Investment Management Inc. purchased a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $243,000. Corient Private Wealth LLC purchased a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $248,000. Finally, Osaic Holdings Inc. increased its holdings in Supernus Pharmaceuticals by 211.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after acquiring an additional 1,328 shares during the period.

Supernus Pharmaceuticals Stock Down 0.4%

SUPN opened at $51.57 on Monday. The business’s fifty day simple moving average is $48.50 and its 200 day simple moving average is $43.17. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $57.65. The stock has a market cap of $2.96 billion, a PE ratio of -151.67, a P/E/G ratio of 0.62 and a beta of 0.72.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The firm had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The business’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.69 earnings per share. As a group, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

Insider Activity

In related news, SVP Frank Mottola sold 20,000 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the transaction, the senior vice president owned 15,496 shares of the company’s stock, valued at approximately $781,153.36. This trade represents a 56.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jack A. Khattar sold 59,900 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the completion of the transaction, the chief executive officer owned 1,206,578 shares in the company, valued at approximately $61,016,649.46. The trade was a 4.73% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 80,610 shares of company stock valued at $4,068,895. Corporate insiders own 8.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on SUPN. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Stifel Nicolaus upped their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research note on Tuesday, September 30th. Bank of America started coverage on Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 target price for the company. Finally, Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $61.60.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.